RE:ONCY's pelareorep enables CAR-T trafficking in solid tumorsLets no forget about this .... Unlike hematological malignancies, solid tumors have proved to be less susceptible to chimeric antigen receptor (CAR)-T cell therapy, which is partially caused by reduced accumulation of therapeutic T cells in tumor site.
Consequently efficient trafficking is the precondition and pivotal step for infused CAR-T cells to exhibit their anti-tumor function and combination with ONCY's oncolytic virus pelareorep enables the creation of a "climate-controlled" tumor microenvironment (TME) for both CAR-T and CPI therapy, and the trafficking of CAR-T cells to the tumor cell surface, which facilitates the T-cells to infiltrate and kill the respective cancer cells, while stimulating the innate and adaptive immune system to "clean-up" what remains.
Dr. Richard Vile of the Mayo Clinic has already demonstrated that boosting CAR-T therapy + pelareorep with a further boost of pelareorep could be "curative" in the treatment of solid tumors.